The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sac-TMT, could add a missing piece thanks to a landmark achieved by its partner, Kelun-Biotech.
Source: FiercePharma
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.